Research location
Düren
North Rhine-Westphalia, Germany
Advertisement
Research activity in Düren
North Rhine-Westphalia, GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 17 trials and 17 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Düren
17 linked trials · page 1 of 1A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT03034915 · 2017-06-16 · 1 site observation
COMPLETED
Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)NCT02299375 · 2014-12-09 · 1 site observation
COMPLETED
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT02236611 · 2014-09-26 · 1 site observation
COMPLETED
The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on TiotropiumNCT01899742 · 2014-09-15 · 1 site observation
COMPLETED
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT02164513 · 2014-06-30 · 1 site observation
COMPLETED
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for ExacerbationsNCT02130193 · 2014-02-13 · 1 site observation
COMPLETED
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2NCT02119286 · 2013-10-01 · 1 site observation
COMPLETED
Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 WeeksNCT01772134 · 2013-01-01 · 1 site observation
COMPLETED
Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary CareNCT01516528 · 2011-11-17 · 1 site observation
COMPLETED
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary DiseaseNCT01316913 · 2011-03-01 · 1 site observation
COMPLETED
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseNCT01313676 · 2011-01-25 · 1 site observation
COMPLETED
Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's DiseaseNCT00708552 · 2008-07-04 · 1 site observation
COMPLETED
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate AlzheimersNCT00490568 · 2007-08-08 · 1 site observation
TERMINATED
Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)NCT00395317 · 2006-12-01 · 1 site observation
COMPLETED
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's DiseaseNCT00348309 · 2006-07-06 · 1 site observation
COMPLETED
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs SyndromeNCT00357097 · 2006-06-01 · 1 site observation
COMPLETED
Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00259909 · 2005-11-02 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.